- Active not recruitingPHASE2
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
This study is testing a new medicine, XEN1101, for people aged 18-75 with focal epilepsy. It aims to see if the medicine can reduce seizures, how safe it is, and if people tolerate it well, when added to their current epilepsy treatments.
For: Focal EpilepsyUnited States · Canada · Georgia - RecruitingPHASE3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This study is testing a new medicine, XEN1101, alongside usual treatments for a specific type of epilepsy seizure called Primary Generalized Tonic-Clonic Seizures (PGTCS). It aims to see if the new medicine helps reduce these seizures and if it's safe for people aged 12 and older.
For: Primary Generalized Tonic-Clonic SeizuresUnited States · Argentina · Australia - Enrolling by invitationPHASE3
An Open-label Study of XEN1101 in Epilepsy
This study looks at a medicine called XEN1101 for people with certain types of epilepsy, including focal epilepsy and tonic-clonic seizures. It focuses on how safe and effective it is over a long time, up to six years, after they've been in a previous study.
For: Focal Epilepsy · Tonic-Clonic SeizuresUnited States · Argentina · Australia